Pluristem Life Systems, Inc. (OTCBB: PLRS) biotechnology company is dedicated to the commercialization of allogeniec cell therapy products for the treatment of severe blood, cardiovascular and autoimmune disorders. The first product planned by the company is dedicated to resolving the global shortfall of matched tissue for bone marrow transplantation by improving the engraftment of umbilical cord blood (UCB). The Company owns GMP early stage facilities and an animal house to conduct research, development and manufacturing of its products.

Pluristem has discovered and patented a process to grow and expand Adult Mesenchymal and Hematopoietic Stem Cells (MCS, HSC). Cell expansion is executed in an environment that mimics natures microstructure of bone marrow and does not include the supplemented growth factors of cytokines. It is for this reason that Pluristem's Technology is to the best of our knowledge the most efficient and safe way to grow Mesenchymal and Hematopoietc stem cells on a production scale for cell therapy products. The first product targets a critical global shortfall of matched tissue for bone marrow transplantation (BMT).

http://www.pluristem.com/